Cover Image
市場調查報告書

糖皮質激素誘導腫瘤壞死因子受體:開發中產品分析

Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365745
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
Back to Top
糖皮質激素誘導腫瘤壞死因子受體:開發中產品分析 Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 57 Pages
簡介

本報告提供以糖皮質激素誘導腫瘤壞死因子受體為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

糖皮質激素誘導腫瘤壞死因子受體 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Ablynx NV
  • Amgen Inc.
  • Apogenix GmbH
  • Bristol-Myers Squibb Company
  • Five Prime Therapeutics, Inc.
  • Incyte Corporation
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Novartis AG
  • OncoMed Pharmaceuticals, Inc.
  • Regeneron Pharmaceuticals, Inc.

藥物簡介

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0185TDB

Summary

Global Markets Direct's, 'Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H1 2016', provides in depth analysis on Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted pipeline therapeutics.

The report provides comprehensive information on the Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18)
  • The report reviews Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) Overview
  • Therapeutics Development
    • Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Products under Development by Stage of Development
    • Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Products under Development by Therapy Area
    • Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Products under Development by Indication
  • Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Products under Development by Companies
  • Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Companies Involved in Therapeutics Development
    • Ablynx NV
    • Amgen Inc.
    • Apogenix GmbH
    • Bristol-Myers Squibb Company
    • Five Prime Therapeutics, Inc.
    • Incyte Corporation
    • MedImmune, LLC
    • Merck & Co., Inc.
    • Novartis AG
    • OncoMed Pharmaceuticals, Inc.
    • Regeneron Pharmaceuticals, Inc.
  • Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Drug Profiles
    • AMG-228 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986156 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FPA-154 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GWN-323 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INCAGN-1876 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LKZ-145 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-1873 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-1248 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-4166 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Agonize GITR for Immunology and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Agonize GITR for Hematological Malignacies and Solid Tumors - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Agonize GITR for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Agonize GITR for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Agonize GITR for Solid Tumor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRX-518 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Featured News & Press Releases
    • Jun 05, 2016: Leap Therapeutics Presents Data from Phase 1 Single Dose Safety Study of Anti-GITR Immunotherapy TRX518 in Patients with Advanced Relapsed or Refractory Solid Tumors at American Society of Clinical Oncology (ASCO) 2016 Annual Meeting
    • Apr 19, 2016: OncoMed Presents GITRL-Fc Research at the AACR Annual Meeting 2016
    • Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate INCAGN01876 at the American Association for Cancer Research (AACR) 2016 Annual Meeting
    • Jan 21, 2016: Agenus Announces Clearance of Investigational New Drug Application by the FDA for anti-GITR Antibody
    • Sep 16, 2015: OncoMed Presents Immuno-Oncology Data for GITRL-Fc Candidate at the Inaugural International Cancer Immunotherapy Conference
    • Apr 05, 2011: Tolerx Presents Preclinical Data On New Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses
    • Feb 09, 2011: Tolerx Presents Preclinical Data On TRX518
    • Dec 14, 2010: Tolerx Initiates Phase I Clinical Trial Of TRX518 For Treatment Of Cancer
    • Dec 01, 2010: Tolerx And Cancer Research Institute Enter Collaboration To Accelerate Development Of TRX518
    • Jun 25, 2010: Tolerx Reports Preclinical Data On TRX518 For Treatment Of Cancer
    • Oct 21, 2008: Laureate To Manufacture Tolerx's TRX518 Antibody
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Ablynx NV, H1 2016
  • Pipeline by Amgen Inc., H1 2016
  • Pipeline by Apogenix GmbH, H1 2016
  • Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Pipeline by Five Prime Therapeutics, Inc., H1 2016
  • Pipeline by Incyte Corporation, H1 2016
  • Pipeline by MedImmune, LLC, H1 2016
  • Pipeline by Merck & Co., Inc., H1 2016
  • Pipeline by Novartis AG, H1 2016
  • Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016
  • Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top